Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’
Cancer undetectable for one in 12 patients in daraxonrasib trial, while nearly all participants’ tumours stopped growing

TL;DR
- Daraxonrasib, a KRAS inhibitor pill, is showing remarkable results in a trial for advanced pancreatic cancer.
- Tumours stopped growing in 90% of patients, and became undetectable in about 8% of participants.
- Survival rates at one year were significantly higher (76.6%) compared to chemotherapy alone (40-45%).
- The drug works by targeting specific mutations that drive tumour growth.
- There is potential for daraxonrasib to be effective against other cancers with similar mutations.
- While promising, further research is needed to determine its long-term efficacy and potential as a cure.